Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 274 full-time employees. The company went IPO on 2021-06-17. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company’s technologies are designed to generate T cells with the ability to persist and self renew while driving durable tumor cytotoxicity, even in the setting of an immunosuppressive tumor microenvironment. Its technologies can be applied in a target agnostic manner to multiple T cell modalities, including chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies. Its product candidates include LYL797, LYL845 and LYL119. The LYL119 is a ROR1 CAR T-cell product designed for enhanced cytotoxicity.